<qa>  What is the goal of this randomised phase IIIII study?Outcomes and Significance - This randomised phase IIIII study aims to compare capecitabine monotherapy with capecitabine plus bevacizumab and capecitabine plus bevacizumab plus MMC in patients with previously untreated metastatic colorectal cancer. 